Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction

Abstract

pressure, and total ICP (area under the curve). Organ-bath studies were performed on corpus cavernosum smooth muscle (CCSM) strips. Nitric oxide synthase (NOS) expression was determined immunohistochemically (IHC) for neuronal (n)NOS and by Western blot analysis for endothelial (e) and inducible (i) NOS protein. RESULTSRats with PBOO showed lower erectile responses than controls. Maximum electrical field stimulation-mediated and endothelium-dependent acetylcholineinduced relaxations and contractile responses to phenylephrine were significantly reduced in CCSM strips from the PBOO group. The NO donor sodium nitroprusside completely relaxed CCSM from rats in all groups. IHC analyses showed decreased expression of nNOS in PBOO groups compared with controls; by contrast, protein expression of eNOS and iNOS was increased. Alfuzosin-treatment partially attenuated functional and molecular changes in penises of PBOO rats. CONCLUSIONRats with PBOO show ED, most likely due to altered NOS expression and NO bioavailability. The α -adrenoreceptor antagonist alfuzosin reversed this ED by altering sympathetic tone, increasing NOinduced relaxation and augmenting blood flow in the penis. This study suggests a rationale for further clinical trials using combinations of α -adrenoceptor antagonists and phosphodiesterase-5 inhibitors in patients with ED and lower urinary tract symptoms. KEYWORDSrat model, partial bladder outlet obstruction, nitric oxide synthase, alfuzosin, erectile function Study Type -Therapy (RCT) Level of Evidence 1b OBJECTIVETo determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective α 1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED). MATERIALS AND METHODSAdult male Sprague-Dawley rats (120) were randomized into four groups: 1, shamoperated; 2, alfuzosin-treated; 3, PBOO; and 4, alfuzosin-treated with PBOO. Groups 3 and 4 were subjected to PBOO for 6 weeks by ligation of the urethra, while groups 2 and 4 rats received daily oral alfuzosin (10 mg/day) for 6 weeks. In vivo erectile responses were monitored by evaluating ratios of intracavernosal pressure (ICP)/mean arterial

The effect of alfuzosin on renal resistive index, urinary electrolytes and β2 microglobulin levels and TGF β-1 levels of kidney tissue in rats with unilateral ureteropelvic junction obstruction

“…Thanks to its ability to inhibit smooth muscle contractions, it has been utilized recently for ensuring smooth passage of ureteral calculi. 12,13 Our aim was to investigate whether alfuzosin has protective effects on tubules and kidneys in partial UPO model in order to benefit from its ability to reduces intraluminal pressure in the ureter by selectively blocking a 1a especially in the proximal ureter.…”

“…Even though the average ARI values were similar, this decrease due to the alfuzosin treatment gives rise to the thought that it might be because of an inhibition ensured sympathicomimetically by alfuzosin indirectly, if not directly. 12,13 The study made by Karakus¸et al, it was shown that ARI is fit to be utilized in diagnosing UPO and that enalapril, an ACE inhibitor used on the treatment group, maintains renal blood flow with its effect on the RAA system and decreases ARI values. 30 Glomerulus sclerosis and collapse, proximal and distal tubule dilation, epithelial degeneration, interstitial fibrosis and inflammation, and vascular congestion were reduced statistically in Group UPT by histopathologically (p < 0.05).…”

“…14 Two weeks were allotted in Group UPT for the ureteropelvic stenosis to become chronic, and then the animals were medicated with Alfuzosin (Xatral XL 10 mg, Sanofi Aventis, Turkey) administered in their drinking water for two weeks. A dose of 10 mg/kg/day of alfuzosin was preferred, an amount previously used on rats (12). Group UPD was just monitored for four weeks without any treatment.…”

“…11 It was shown that 10 mg/kg alfuzosin treatment in rats has an antioxidant effect, regulates nitric oxide (NO) release, and decreases the sympathomimetic effects. 12,13 Apart from the aforementioned effects, it was intended to investigate whether it has protective effects on tubules and kidneys by using it in partial UPO model for the first time in literature, due to the fact that it reduces intraluminal pressure in the ureter.…”

Usefulness of electromyography of the cavernous corpora (CC EMG) in the diagnosis of arterial erectile dysfunction

“…These data are in accordance with our hypothesis about CC-EMG and Eco-Doppler relationship. 25 We did not carry out a reinjection in any patient. We applied the standard dose of 20 mg of Caverject to all the patients.…”